June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Visual Outcomes post-PPV for Tractional Retinal Detachment or Vitreous Hemorrhage in the Intelligent Research in Sight (IRIS) Registry
Author Affiliations & Notes
  • Ashton Tristan Perlroth
    Ophthalmology, Stanford University, Stanford, California, United States
  • Arthur Brant
    Ophthalmology, Stanford University, Stanford, California, United States
  • Suzann Pershing
    Spencer Center for Vision Research, Byers Eye Institute, Stanford University, Stanford, California, United States
    Ophthalmology, VA Palo Alto Health Care System, Palo Alto, California, United States
  • Kapil Mishra
    Ophthalmology, Stanford University, Stanford, California, United States
  • Henry Bair
    Ophthalmology, Stanford University, Stanford, California, United States
  • Christine Xu
    Ophthalmology, Stanford University, Stanford, California, United States
  • Diana V Do
    Ophthalmology, Stanford University, Stanford, California, United States
    Ophthalmology, VA Palo Alto Health Care System, Palo Alto, California, United States
  • Footnotes
    Commercial Relationships   Ashton Perlroth None; Arthur Brant None; Suzann Pershing NEI P30EY026877, Research to Prevent Blindness Inc, Code F (Financial Support); Kapil Mishra None; Henry Bair None; Christine Xu None; Diana Do Allergan, Kodiak Sciences, Novartis, Regeneron, Code C (Consultant/Contractor), Steve Zelenik Retina Research Fund, Gregory Wallace Retina Research Fund, Boeringer Ingelheim, Code F (Financial Support)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 584 – A0149. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ashton Tristan Perlroth, Arthur Brant, Suzann Pershing, Kapil Mishra, Henry Bair, Christine Xu, Diana V Do; Visual Outcomes post-PPV for Tractional Retinal Detachment or Vitreous Hemorrhage in the Intelligent Research in Sight (IRIS) Registry. Invest. Ophthalmol. Vis. Sci. 2022;63(7):584 – A0149.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Patients with active Proliferative Diabetic Retinopathy (PDR) who develop non-clearing vitreous hemorrhage (VH) and macula-involving tractional retinal detachment (TRD) often undergo surgery with pars-plana vitrectomy (PPV). Our understanding of their visual prognoses remains limited. The purpose of this study was to determine visual acuity outcomes after PPV for TRD and VH patients in the IRIS Registry.

Methods : Patients were identified in the IRIS registry who received a new diagnosis of PDR who then developed either VH or TRD and underwent PPV within 90 days. The distribution of visual acuity in logMAR was evaluated at time points three months pre-PPV to one-year post-PPV, and the difference in mean logMAR one-year post-PPV was compared to one-week pre-PPV with an independent t-test. We further stratified by pseudophakic and phakic patients.

Results : Between 2016 and 2018, 1851 PDR eyes who developed VH underwent PPV and 553 with TRD underwent PPV. 18.8 % of VH eyes were pseudophakic preoperatively compared with 19.2% of TRD eyes, compared with 36.4% and 39.4% after one year post PPV. For TRD, preoperative visual acuity was 1.62 (phakic) and 1.59 (pseudophakic) logMAR and one-year postoperative VA was 1.35 and 1.35, and the difference was not significant (p=0.189 and p=0.260). For VH, preoperative visual acuity was 1.65 (phakic) and 1.73 (pseudophakic) logMAR and one-year postoperative VA was 0.84 and 0.83, and the difference was not significant (p=0.001 and p=0.001). On average, phakic eyes gained 0.82 logMAR and pseudophakic eyes gained 0.89 logMAR. Of note, for VH, the vast majority of improvement came within the first postoperative month.

Conclusions : Patients with PDR who developed TRD and underwent PPV on average presented legally blind (1.62 and 1.59 for phakic and pseudophakic) and did not significantly improve one year after PPV (1.35 and 1.35). Patients with PDR who developed VH and underwent PPV on average presented legally blind (1.66 and 1.73 for phakic and pseudophakic eyes) and improved significantly to 0.84 and 0.83 logMAR after one year, with the vast majority of improvement coming in the first month (1.06 and 1.13). For both TRD and VH, 1 week preoperative and 12 month postoperative VA was not significantly different between phakic and pseudophakic patients, and TRD and VH underwent post-PPV cataract surgery at similar rates.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×